Defined multi-conjugates oligonucleotides

US11767531B2 · kind B2 · utility

Assignee

• MPEG LA, L.L.C. · US

Inventors

• Philipp Hadwiger · Kulmbach, DE
• Hans-Peter Vornlocher · Bayreuth, DE
• Jonathan Miles Brown · Bethesda, US
• James E. Dahlman · Atlanta, US
• Kristin K.H. Neuman · Chevy Chase Section Five, US

Key dates

• Filing date: May 18, 2022
• Grant date: Sep 26, 2023
• Expiry date: May 18, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/51
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.